Get a Quote
Receive a tailored pricing based on your needs.
- Choose license type
- Multiple user options
- Custom scope & coverage
- Fast turnaround
"Designing Growth Strategies is in our DNA"
The global mechanical circulatory support devices market size was valued at USD 3.59 billion in 2025. The market is projected to grow from USD 4.01 billion in 2026 to USD 8.58 billion by 2034, exhibiting a CAGR of 10.0% during the forecast period.
Mechanical Circulatory Support (MCS) devices are specialized medical machines that assist or replace the pumping function of a weakened heart to keep blood moving through the body. These devices improve blood flow to vital organs and reduce the workload on the heart. Certain extracorporeal support systems may also provide blood oxygenation when integrated with an oxygenator. Market growth is attributed to the increasing prevalence of cardiovascular diseases, particularly heart failure.
Abbott, ABIOMED, Getinge, Teleflex Incorporated, and Berlin Heart held the highest market share in 2025, supported by established brand recognition, broad product portfolios, and extensive global distribution networks.
Shift Toward Advanced Pump-Based MCS Technologies to Emerge as a Key Trend
The market is witnessing a shift toward more advanced pump technologies that can provide improved hemodynamic support with improved efficiency and durability. In temporary mechanical circulatory support, catheter-based pumps are gaining adoption as they provide direct ventricular support and higher blood flow compared with traditional IABP systems.
On the other hand, the durable MCS devices are increasingly utilizing magnetically levitated rotary pumps to reduce mechanical contact and wear inside the device. Key products such as the HeartMate 3 have helped in the establishment of this technology in long-term support. Moreover, as healthcare facilities expand their use of these technologies, catheter-based and magnetically levitated pumps are anticipated to gain importance.
Download Free sample to learn more about this report.
Growing Use of Temporary MCS in Cardiogenic Shock and High-Risk PCI Fuels Market Growth
Over the past few years, the use of temporary mechanical circulatory support devices has increased in cardiogenic shock, acute heart failure, and high-risk PCI. Catheter-based heart pumps can be implanted or inserted rapidly in appropriate clinical settings. Moreover, their adoption is growing due to greater physician experience, wider availability of catheterization laboratories equipped to provide mechanical circulatory support, and the use of dedicated shock-treatment protocols. Furthermore, the increasing prevalence of heart failure and related cardiac conditions contributes to the market growth.
Market Drivers - Impact & CAGR Contribution (2026–2034)
| Rank | Market Drivers | Expected Impact on Market Growth | Estimated Gross Market Growth Contribution (USD Billion) (2026-2034) |
Impact: 2026-2028 | Impact: 2029-2031 | Impact: 2032-2034 |
|---|---|---|---|---|---|---|
| 1 | Growing use of temporary MCS in cardiogenic shock and high-risk PCI | High | 1.75 | High | High | High |
| 2 | Rising burden of advanced heart failure, cardiogenic shock and donor-heart shortage | High | 1.45 | High | High | High |
| 3 | Expansion of catheter-based temporary MCS in cardiogenic shock and high-risk PCI | Medium-High | 1.2 | High | High | Medium |
| 4 | Durable LVAD technology improvements and broader long-term support eligibility | Medium-High | 0.95 | Medium | High | High |
| 5 | Expansion of advanced cardiac centers and reimbursement/coverage pathways | Medium | 0.83 | Medium | Medium | Medium |
| 6 | Emerging-market commercialization and tertiary cardiac infrastructure growth | Low | 0.44 | Low | Low | Low |
| Total Gross Growth Contribution | 6.62 | |||||
Source: Fortune Business Insights
Download Free sample For In-Depth Market Drivers & Impact Forecasts
Risk of Device-Related Complications to Limit Market Growth
Although mechanical circulatory support devices provide life-saving support to critically ill patients, their invasive nature carries risks of serious complications such as bleeding, vascular injury, blood clots, stroke, hemolysis, infection, and device malfunction. Such complications increase the need for physician training, careful patient selection, and continuous monitoring, potentially limiting the adoption of these devices.
Safety concerns may also lead to regulatory actions, labeling updates, or product recalls. For instance, in March 2024, the FDA announced a Class I recall involving a correction to the instructions for use of certain Impella left-sided blood pumps following reports of 129 serious injuries and 49 reported deaths, associated with the risk of cardiac perforation. Such safety concerns may increase hospitals' caution when adopting MCS devices. This is anticipated to hinder the mechanical circulatory support devices market growth over the forecast period.
Market Restraints - Impact & Negative CAGR Contribution (2026–2034)
| Rank | Market Restraints | Expected Impact on Market Growth | Estimated Reduction in Market Size (USD Billion) (2026-2034) |
Impact: 2026-2028 | Impact: 2029-2031 | Impact: 2032-2034 |
|---|---|---|---|---|---|---|
| 1 | Risk of Device-Related Complications to Limit Market Growth | High | 0.82 | High | High | High |
| 2 | High device/therapy cost and reimbursement or hospital-budget constraints | Medium-High | 0.57 | High | High | Medium |
| 3 | Limited specialist centers and trained multidisciplinary MCS workforce | Medium | 0.42 | Medium | Medium | Medium |
| 4 | Others (regulatory delays, supply-chain constraints, patient eligibility limits and competing therapies) | Low | 0.24 | Low | Low | Low |
| Total Market Reduction | 2.05 | |||||
Source: Fortune Business Insights
Download Free sample For In-Depth Market Restraints & Risk Analysis
Growing Adoption of MCS in Emerging Markets to Create Lucrative Growth Opportunities
Emerging markets across China, India, Southeast Asia, Latin America, and the Gulf Cooperation Council (GCC) countries offer strong growth potential for the adoption of mechanical circulatory support devices. Adoption in these regions is generally lower than in North America and Europe, but the number of advanced cardiac centers and specialists is increasing.
Also, local manufacturing could improve device accessibility by reducing dependence on imports by reducing dependence on expensive imported products. Furthermore, adoption is expected to increase particularly in urban hospitals and specialized cardiac centers. Additionally, distributor partnerships, improved reimbursement mechanisms, local regulatory approvals, and greater affordability could support wider adoption.
Limited Availability of Specialized MCS Centers and Skilled Professionals to Challenge the Market Growth
In several countries, particularly emerging economies, the availability of multidisciplinary MCS teams remains limited, involving cardiac surgeons, heart-failure specialists, interventional cardiologists, intensivists, perfusionists, nurses, and other trained staff. This restricts MCS adoption, particularly outside major tertiary and cardiac centers.
Moreover, specialized MCS centers are often concentrated in major metropolitan areas, restricting MCS adoption in rural areas and potentially limiting market growth.
Growing Adoption in Cardiogenic Shock and High-Risk PCI Boosted Intracorporeal Catheter-Based Heart Pumps Segment Dominance
Based on product type, the market is segmented into intracorporeal catheter-based heart pumps, implantable ventricular assist devices, extracorporeal & paracorporeal circulatory support devices, intra-aortic balloon pump systems, total artificial hearts, and others. The intracorporeal catheter-based heart pumps segment is further sub-segmented into left-heart support pumps, right-heart support pumps, and others. The implantable ventricular assist devices segment is sub-classified into LVADs and RVADs & BiVADs. The extracorporeal & paracorporeal circulatory support devices segment is subdivided into left-heart support systems, right-heart support systems, and biventricular support systems. The intra-aortic balloon pump systems segment is sub-segmented into IABP consoles and intra-aortic balloon catheters.
The intracorporeal catheter-based heart pumps segment accounted for the largest global mechanical circulatory support devices market share in 2025. The segment’s growth is mainly driven by their growing utilization in cardiogenic shock and high-risk PCI procedures, where rapid short-term circulatory support is required. Moreover, these pumps are generally used for individual treatment episodes. This is expected to create a repetitive demand as procedure volumes increase.
The implantable ventricular assist devices segment is projected to grow at a 9.1% CAGR during the forecast period.
To know how our report can help streamline your business, Speak to Analyst
Adults Segment Led Market Due to High Burden of Cardiac Conditions
By patient group, the market is segmented into adults and pediatric.
The adults segment accounted for the largest market share in 2025. The segment’s growth is attributed to a higher prevalence of advanced heart failure, cardiogenic shock, complex PCI, and post-cardiotomy complications among adult patients. Additionally, the growing geriatric population is anticipated to drive the segment’s growth in the coming years.
The pediatric segment is anticipated to grow at a CAGR of 12.8% over the forecast period.
Cardiogenic Shock & Acute Cardiac Failure Segment Led Market Due to Increasing Utilization of Temporary MCS
By application, the market is classified into chronic advanced & end-stage heart failure, cardiogenic shock & acute cardiac failure, high-risk PCI & procedural hemodynamic support, post-cardiotomy circulatory failure, and others.
The cardiogenic shock & acute cardiac failure segment accounted for the largest market share in 2025. The segment’s dominance is mainly due to the increasing prevalence of cardiogenic shock & acute cardiac failure and increasing use of temporary MCS devices to stabilize critically ill patients quickly. Furthermore, the segment is set to acquire a 34.6% share in 2026.
The chronic advanced & end-stage heart failure segment is expected to grow at a CAGR of 7.6% during the forecast period.
Availability of Advanced Cardiac Care Infrastructure Supported Hospitals & ASCs Segment Dominance
On the basis of end-user, the market is segmented into hospitals & ASCs, specialty clinics, and others.
In 2025, the hospitals & ASCs segment dominated the market. Durable VAD implantation, post-cardiotomy support, cardiogenic shock treatment, and total artificial heart (TAH) procedures require advanced medical infrastructure, which hospitals and ASCs offer. This is expected to drive the segment’s growth during the forecast period. Furthermore, the segment is set to hold a 94.0% market share in 2026.
The specialty clinics segment is projected to grow at a CAGR of 12.2% during the forecast period.
Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America Mechanical Circulatory Support Devices Market Size, 2025 (USD Billion)
To get more information on the regional analysis of this market, Download Free sample
North America accounted for the largest share in 2024, valued at USD 1.71 billion, and maintained its leading position in 2025, with USD 1.95 billion. The region’s dominance is supported by strong adoption of temporary heart pumps in the U.S., well-established VAD programs, advanced transplant centers, and favorable reimbursement systems. For instance, as of September 2026, Transplants.org, Inc. stated that there are approximately 150 active heart transplant programs in the U.S.
In 2026, the U.S. is anticipated to reach USD 2.05 billion, accounting for approximately 51.1% of global sales.
Europe is projected to record a CAGR of 9.2% during the forecast period, the second-highest globally. The market is expected to reach USD 0.82 billion in 2026. The region’s growth is attributed to the presence of major players and availability of key professionals in the U.K., Germany, France, and Italy.
The U.K. market is projected to reach USD 0.14 billion in 2026, representing approximately 3.6% of global sales.
The market in Germany is expected to reach USD 0.18 billion in 2026, accounting for approximately 4.5% of global revenues.
In 2026, the market in Asia Pacific is projected to reach approximately USD 0.80 billion, making it the third-largest market. The region’s growth is attributable to a large patient pool in the region and growing physician preference for MCS devices due to key advancements in such devices.
The market in Japan is projected to reach approximately USD 0.20 billion in revenue in 2026, representing nearly 5.0% of global sales.
In 2026, the market in China is anticipated to reach USD 0.27 billion, accounting for approximately 6.7% of global sales.
In 2026, the market in India is anticipated to reach USD 0.09 billion, accounting for approximately 2.3% of global sales.
Latin America and the Middle East & Africa are anticipated to witness moderate growth during the forecast period. The market in Latin America is estimated to reach approximately USD 0.13 billion in 2026. Market growth is due to growing awareness of mechanical circulatory support devices in the emerging countries of the region. The Middle East & Africa market is mainly driven by key players entering the market to capture untapped opportunities in low-income areas.
In 2026, the GCC market is estimated to reach approximately USD 0.06 billion, representing around 1.5% of global revenues.
Established Global Presence and Product Portfolios Support Competitive Position of Leading Companies
In 2025, Abbott, ABIOMED, Getinge, Teleflex Incorporated, and Berlin Heart were identified among the leading market participants. The significant share of these companies is attributed to their strong global footprint and diversified product portfolios. Moreover, other prominent players are focusing on strategic growth initiatives such as mergers and acquisitions, strategic collaborations, and partnerships, and increasing investments to strengthen their competitive positions during the forecast period.
The report offers an in-depth assessment of the global mechanical circulatory support devices market, covering its key segments and major growth drivers, restraints, opportunities, challenges, and market trends. It also evaluates technological advancements, key industry developments, product approvals, heart failure prevalence/incidence, the competitive landscape, company market share analysis, and profiles of leading market participants.
Request for Customization to gain extensive market insights.
| ATTRIBUTE | DETAILS |
| Study Period | 2021-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2021-2024 |
| Growth Rate | CAGR of 10.0% from 2026 to 2034 |
| Unit | Value (USD Billion) |
| Segmentation | By Product Type, Patient Group, Application, End-user, and Region |
| By Product Type |
|
| By Patient Group |
|
| By Application |
|
| By End-user |
|
| By Region |
|
Fortune Business Insights says that the global market value stood at USD 3.59 billion in 2025 and is projected to reach USD 8.58 billion by 2034.
In 2025, the market value in North America stood at USD 1.95 billion.
The market is expected to exhibit a CAGR of 10.0% during the forecast period.
By product type, the intracorporeal catheter-based heart pumps segment led the market.
Growing use of temporary MCS in cardiogenic shock and high-risk PCI fuels market growth.
Abbott, ABIOMED, Getinge, Teleflex Incorporated, and Berlin Heart are among the top players in the market.
North America dominated the market in 2025.
Get 30-60 hrs Free Customization
Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.
Related Reports
Get In Touch With Us
US +1 833 909 2966 ( Toll Free )
Receive a tailored pricing based on your needs.
Discuss your questions with our industry experts.
Have questions? Get quick answers before you purchase.